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Abstract
The sample size of a clinical trial relies on information about nuisance parameters such
as the outcome variance. When no or only limited information is available, it has been
proposed to include an internal pilot study in the design of the trial. Based on the
results of the internal pilot study, the initially planned sample size can be adjusted. In
this paper, we study blinded sample size re-estimation in the ‘gold standard’ design for
normally distributed outcomes. The ‘gold standard’ design is a three-arm clinical trial
design which includes an active and a placebo control in addition to an experimental
treatment. We compare several sample size re-estimation procedures in a simulation
study assessing operating characteristics including power and type I error. We find that
sample size re-estimation based on the popular one-sample variance estimator results
in overpowered trials. Moreover, sample size re-estimation based on unbiased variance
estimators such as the Xing-Ganju variance estimator results in underpowered trials,
as it is expected since an overestimation of the variance and thus the sample size is in
general required for the re-estimation procedure to eventually meet the target power.
Moreover, we propose an inflation factor for the sample size re-estimation with the Xing-
Ganju variance estimator and show that this approach results in adequately powered
trials. Due to favorable features of Xing-Ganju variance estimator such as unbiasedness
and a distribution independent of the group means, the inflation factor does not depend
on the nuisance parameter and, therefore, can be calculated prior to a trial.
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1. Introduction
Sample size planning for clinical trials is often accompanied by difficulties arising
from uncertainty about the primary outcome. The implicated misspecification of nui-
sance parameters during the sample size planning might result in a severely under- or
overpowered trial potentially having a negative effect on the success of the study. To
limit the effect of nuisance parameter misspecification, trial designs can allow for adjust-
ing the initially set sample size while the trial is on-going. This adjustment is referred to
as sample size re-estimation or sample size re-calculation. The sample size re-estimation
can either be based on treatment effect estimates or on nuisance parameter estimates
[1]. In this manuscript, we focus on sample size re-estimation based on nuisance pa-
rameter estimates. Wittes and Brittain [2] proposed to perform the re-estimation with
data from a so-called internal pilot study which data are subsequently also incorpo-
rated into the final statistical analysis. The re-estimation itself can be performed with
either blinded or unblinded data [3]. In general, unblinding has the disadvantage of
potentially introducing a bias [4] and is also not recommended from a regulatory point
of view [5, 6]. For a more detailed discussion of sample size re-estimation, we refer the
reader to the reviews [1, 3].
In this manuscript, we study blinded sample size re-estimation in three-arm trials
in the ‘gold standard’ design with normally distributed data. The ‘gold standard’ de-
sign includes an experimental treatment, an active control referred to as reference, and
a placebo. This trial design allows assessing both non-inferiority of the experimental
treatment compared to the reference as well as the superiority of the experimental treat-
ment or the reference over placebo. These superiorities are often considered to prove
assay sensitivity, the ability of a trial to distinguish an effective from a non-effective
treatment. For the ‘gold standard’ design multiple hypotheses and testing strategies
have been proposed [7–10]. and planning and analzing studies in this design received
great attention in past years [11–18].
Blinded sample size re-estimation has already been studied extensively for two-arm
trials with normally distributed data [19, 20, 22–25]. For this trial design, the nui-
sance parameter is the outcome variance which is also referred to as within group vari-
ance. Particular emphasis was put on approaches of estimating the nuisance parameter
blinded. The best results in terms of meeting the target power and controlling the type
I error rate were achieved when the sample size is re-estimated based on the one-sample
variance estimator which simply estimates the outcome variance by the sample variance
of the blinded data set. This approach works particularly well in two-arm trials since
the within-group variance, i.e. the nuisance parameter, dominates the between-group
variance. Thus, the one-sample variance estimator which estimates a linear combination
of within-group variance and between-group variance overestimates the within-group
variance only moderately. This overestimation of the nuisance parameter and thus the
sample size is in general required for the re-estimation procedure to eventually meet the
target power. Especially for smaller pilot studies, sample size re-estimation procedures
with unbiased nuisance parameter estimation result in underpowered trials [24].
This article is structured as follows. We discuss examples of clinical trials in essential
hypertension and in schizophrenia in Section 2. In Section 3, we describe the statistical
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model, the statistical hypotheses, and the sample size planning. Section 4 starts with
a discussion of blinded variance estimators and the resulting sample size re-estimation
procedures. Then, the performance of the sample size re-estimation procedures is as-
sessed in a Monte Carlo simulation study. In Section 5, we propose an inflation factor
for the sample size re-estimation approach based on the Xing-Ganju variance estimator
and assess the operating characteristics of the proposed method in a Monte Carlo sim-
ulation study. The results are discussed in Section 6. We conclude with the appendix
about the distribution of the blinded variance estimators.
2. Clinical trial examples
In this section, we have a closer look at two clinical trials with active and placebo
control in hypertension and schizophrenia. We briefly provide some background on
those diseases and then present results of clinical trials.
2.1. A trial in essential hypertension
A recent position paper of the European Society of Cardiology [26] recommends
adaptive clinical trial designs such as designs including sample size re-estimation as
one strategy to improve clinical trials for cardiovascular disease. One of the modifiable
risk factors for cardiovascular disease is essential hypertension [27]. A clinical trial
in essential hypertension which included both an active and a placebo control was
published by Krum et al. [28]. This trial included a placebo control, Enalapril as an
active control, and several doses of Bosentan as the experimental treatment. Table 1
shows the change from baseline in diastolic and systolic blood pressure for the placebo
control, the active control Enalapril, and one of the doses of the experimental treatment
Bosentan (500 mg). For the purpose of illustration, we focus here on one dose of
Bosentan ignoring the others.
Table 1: Changes from baseline to after treatment in blood pressure as reported in [28, Table 2].
Placebo Enalapril Bosentan 500 mg
N 45 46 45
Mean change (SE) in diastolic pressure -1.8 (1.0) -5.8 (1.0) -5.7 (1.0)
Mean change (SE) in systolic pressure -0.9 (1.7) -9.0 (1.7) -8.4 (1.7)
Due to the similarity of the sample sizes and the identical standard errors, it can be
concluded that the outcome variance is identical between the groups. From Table 1 the
standardized effect (µP −µR)/σ can be estimated to be approximately 0.6 and 0.71 for
the diastolic and systolic blood pressure, respectively. These effects will be considered
later on when selecting the scenarios for the Monte Carlo simulation study comparing
the various sample size re-estimation procedures.
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2.2. A trial in schizophrenia
Schizophrenia is a mental illness which affects a person’s social behaviour [29]. As
a recent meta-analysis highlighted, clinical trials in schizophrenia often include both
an active control and a placebo control [30]. The Positive and Negative Syndrome
Scale (PANSS) is an often considered outcome measure in such trials. The PANSS was
introduced by Kay et al. [31] who also showed that the distribution of the PANSS for
schizophrenics can be approximated by a normal distribution. A recent study by Loebel
et al. [32] assessed the safety and efficacy of Lurasidone for treating schizophrenia. The
study included Quetiapine XR as an active control and a placebo control. The results
of the LS mean change of PANSS from baseline to week 6 are summarized in Table 2.
Table 2: PANSS change from baseline to week 6 as reported in [32, Table 2]. Change is measured as
LSMC (Least-Squares Mean Change).
Lurasidone 80 Lurasidone 160 Quetiapine XR 600 Placebo
N 125 121 116 120
LSMC (SE) -22.2 (1.8) -26.5 (1.8) -27.8 (1.8) -10.3 (1.8)
The standard error of the mean change for the different treatment groups is identical
and with the group specific sample sizes being similar, the outcome variance can be
assumed to be identical. The standardized effect (µP − µR)/σ can be estimated to be
approximately 0.9.
3. Statistical model, hypothesis testing, and sample size planning
3.1. Statistical model and global hypothesis
The observations in the experimental treatment (E), reference (R), and placebo (P)
group are modeled as normally distributed random variables
Xki ∼ N
(
µk, σ
2
)
, i = 1, . . . , nk, k = E,R, P.
The variance σ2 is assumed to be identical across the three treatment groups. Through-
out this manuscript, we assume that smaller values of µk are better. The total sample
size is given by n = nE + nR + nP . The ratio of the group sample size and the total
sample size is denoted as wk = nk/n. In this manuscript, we focus on assessing the
non-inferiority of the experimental treatment compared to the reference. Several ap-
proaches for formulating hypotheses in the ‘gold standard‘ design and the respective
testing strategies have been proposed and discussed [8–10, 33, 34]. We consider non-
inferiority of the experimental treatment compared to the reference as the statistical
testing problem
HER0 : µE − µR ≥ δER vs. H
ER
1 : µE − µR < δER,
with δER > 0 the non-inferiority margin. Non-inferiority is demonstrated if the hypoth-
esis HER0 can be rejected. In addition to the non-inferiority hypothesis, the superiority
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of the experimental treatment and the reference over placebo, respectively, are assessed
by testing the statistical hypotheses
HEP0 : µP − µE ≤ δEP vs. H
EP
1 : µP − µE > δEP ,
HRP0 : µP − µR ≤ δRP vs. H
RP
1 : µP − µR > δRP .
The superiority margins δEP and δRP must be non-negative. We consider a trial in the
‘gold standard’ design to be successful if the non-inferiority and both superiorities can
be demonstrate simultaneously. This leads to the intersection-union test problem
H0 : H
ER
0 ∪H
EP
0 ∪H
RP
0 vs. H1 : H
ER
1 ∩H
EP
1 ∩H
RP
1 .
It is worth noting that the re-estimation procedures discussed in this manuscript also
apply when the global hypothesis is defined as the union of the local hypothesis HER0
and HEP0 , that is when the superiority of the reference to placebo is not tested, or
HER0 and H
RP
0 , that is when the superiority of the experimental treatment to placebo
is not tested. The re-estimation procedures do not depend on the formulation of the
global hypothesis because the estimation of the nuisance parameter, that is the outcome
variance, is performed independently of any hypothesis.
3.2. Planning and analyzing three-arm trials
The global hypothesis H0 is tested at a significance level α by testing the three local
hypotheses HER0 , H
EP
0 , and H
RP
0 at the same level α, respectively. In other words, no
multiplicity adjustment is required for testing the global hypothesis H0 [35]. The local
hypotheses can each be tested by e.g. one-sided Student’s t-tests. The power of the
test procedure for the global hypothesis can be approximated by a multivariate normal
distribution [34], that is
B(n) = Φ

tα,νER − δ
∗
ER − δER
σ
√
1
nE
+ 1
nR
, tα,νRP −
δ∗RP + δRP
σ
√
1
nR
+ 1
nP
, tα,νEP −
δ∗EP + δEP
σ
√
1
nE
+ 1
nP

 , (1)
with δ∗ij = µi − µj, (i, j) = (E,R), (R,P ), (E, P ), the mean differences in the alter-
native and νij = ni + nj − 2 the degrees of freedom of the t-distribution. Here, Φ(·)
is the cumulative distribution function of the three-dimensional multivariate normal
distribution N3(0,Σ) with the covariance matrix
Σ =


1 − 1√(
1+
nR
nE
)(
1+
nR
nP
) 1√(
1+
nE
nR
)(
1+
nE
nP
)
− 1√(
1+
nR
nE
)(
1+
nR
nP
) 1 1√(
1+
nP
nR
)(
1+
nP
nE
)
1√(
1+
nE
nR
)(
1+
nE
nP
) 1√(
1+
nP
nR
)(
1+
nP
nE
) 1


. (2)
Then, the required sample size to test the global hypothesis H0 with a power of 1 − β
for a given alternative (δ∗ER, δ
∗
RP , δ
∗
EP ) is the smallest natural number n for a given
allocation (wE, wR, wP ) such that the power B(n) is equal to or greater than the target
power 1− β, that is
n = min {n˜ ∈ N : B(n˜) ≥ 1− β} . (3)
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4. Re-estimation procedures and their performance
In this section, sample size re-estimation strategies from two-arm trials with nor-
mally distributed endpoints [24, 36] are transferred to three-arm trials. The sample
size re-estimation in three-arm trials in the ‘gold standard’ design with normal data is
conducted by replacing the variance σ2 in the sample size formula (1) by an estimate
σˆ2 obtained from the results of the internal pilot study. Therefore, in this section we
start by presenting various approaches for estimating the variance σ2. Particular at-
tention is paid to approaches which maintain the blinding of the internal pilot study.
The unblinded variance estimator will be included for the sake of comparison. The
performance of the resulting re-estimation procedures are then compared considering
the global hypothesis H0. The performance characteristics of interest are power and
type I error rate.
4.1. Estimating the nuisance parameter
Throughout this section, the sample Y1, . . . , Yn1 denotes the blinded observations
from the internal pilot study with n1 being the total sample size of the internal pilot
study.
Unblinded pooled variance estimator The idea of re-estimating the sample size based
on unblinded data using the sample variance goes back to Stein (1945) [21] and
was introduced to clinical trials by Wittes and Brittain (1990) [2]. Here, the
nuisance parameter σ2 can be estimated unbiased by the pooled group specific
sample variances, that is
σˆ2Pool =
(n1,E − 1)σˆ2E + (n1,R − 1)σˆ
2
R + (n1,P − 1)σˆ
2
P
n1 − 3
.
Here, n1,k (k = E,R, P ) are the group specific sample sizes in the pilot phase.
Internal pilot study designs using this unblinded variance estimator have been
studied extensively by numerous authors [37–42].
Blinded one-sample variance estimator Kieser and Friede (2003) [20] proposed to es-
timate the nuisance parameter by the sample variance of the blinded sample,
i.e.
σˆ2OS =
1
n1 − 1
n1∑
i=1
(
Yi − Y¯·
)2
.
It should be noted, that this estimator is unbiased if and only if the group means
are identical but biased otherwise.
Blinded adjusted one-sample variance estimator As shown for two-arm trials by Gould
and Shih (1992) [19], under the planning alternative, an unbiased estimator for
the nuisance parameter is obtained by adjusting the blinded one-sample variance
estimator by its bias. In the setting considered here, the estimator σˆ2OS has a bias
of
Bias(σˆ2OS, σ
2) =
n
n1 − 1
∆2PR
(
w1,E(∆
∗)2 + w1,R − (w1,E∆
∗ + w1,R)
2
)
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with ∆PR = µP − µR, ∆∗ = (µP − µE)/(µP − µR), and w1,k = n1,k/n1. The
calculation of the bias in shown in the appendix. An unbiased estimator for the
nuisance parameter σ2 is given by
σˆ2OSU = σˆ
2
OS − Bias(σˆ
2
OS, σ
2).
This estimator is only unbiased when the assumptions about the parameters
∆PR and ∆
∗ are correct. When applied in the context of blinded sample size
re-estimation, the parameters ∆PR and ∆
∗ are calculated under the alternative
hypothesis H1.
Blinded variance estimator by Xing and Ganju [36] In a randomized block design with
balanced blocks of length m and Tk the sum of the observations in block k, an
unbiased blind estimator for the nuisance parameter σ2 is given by
σˆ2XG =
1
n1 −m
∑
k
(
Tk − T¯·
)2
with T¯· denoting the mean of the sums Tk.
4.2. Sample size re-estimation
The sample size of a three-arm trial depends on the assumed effect sizes δ∗ER, δ
∗
RP ,
and δ∗EP , on the non-inferiority and superiority margins δER, δRP , and δEP , on the
sample size allocation (wE , wR, wP ), and on the variance σ
2. The blinded sample size
re-estimation is performed by substituting the variance σ2 in Formula (1) by a blind
variance estimator and then calculating the sample size as defined in Equation (3). The
resulting re-estimated sample size is denoted as nˆreest. However, the re-estimated sample
size is not necessarily the final sample size of the trial. For instance, the final sample
size cannot be smaller than the pilot study size n1. Wittes and Brittain [2] proposed
that the final sample size nˆfinal should not be smaller than the initially planned sample
size nˆ, meaning that the sample size re-estimation cannot reduce the initially planned
sample size. Birkett and Day [44], however, suggested to also consider reducing the
initially planned sample size in which case the final sample size would be the maximum
of the pilot study size n1 and the re-estimated sample size nˆreest. Gould [45] noted to
additionally define an upper limit for the final sample size nˆfinal since too large sample
sizes are often not feasible in practice due to limitation of resources. In this manuscript,
we allow for downsizing the initially planned sample size but we do not introduce an
upper limit for the final size size. Therefore, the final sample size is given by
nˆfinal = max {n1, nˆreest} .
4.3. Power and sample size of the re-estimation procedures
In this subsection we compare the power and the distribution of the final sample
size for the various re-estimation procedures by means of a Monte Carlo simulation
study. The scenarios of the Monte Carlo simulation study are motivated by the exam-
ples in essential hypertension and schizophrenia from Section 2. Therefore, we choose
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Table 3: Scenarios for the Monte Carlo simulation study.
Parameter Values
One-sided significance level α 0.025
Target power 1− β 0.8
Superiority margins δEP , δRP δEP = δRP = 0
Non-inferiority margin δER δER = 0.3
Means µE and µR in the alternative H1 µE = µR = 0
Mean µP in the alternative H1 µP = 0.6, 0.9
Standard deviation σ in the alternative H1 σ = 1
Sample size allocation nE : nR : nP 1:1:1, 3:2:1
Pilot study sample size n1 n1 = 30, 60, . . . , 390
the effect sizes (µP −µR)/σ = 0.6, 0.9. The parameter combination in the alternative is
that the experimental treatment and the reference are equal, that is µE = µR. Table 3
lists the parameters considered in the simulation study. For each scenario, we perform
15 000 Monte Carlo replications which corresponds to a Monte Carlo error of smaller
than 0.0033 for a simulated power of 0.8. The internal pilot studies are generated with
the same allocation as the final trial. The Xing-Ganju estimator requires a randomized
block design. Here, we consider block randomizations with block sizes three and six for
allocations 1:1:1 and 3:2:1, respectively. In Table 4 the samples sizes for a fixed design
according to Equation (3) are listed. In Figure 1, the power of the various sample
Table 4: Sample sizes for a power of 80% in the fixed design.
Mean µP Allocation Sample size n
0.6 1:1:1 525
3:2:1 452
0.9 1:1:1 525
3:2:1 438
size re-estimation procedures are shown for the scenarios specified in Table 3. Figure
1 shows that none of the considered sample size re-estimation procedures meets the
target power for all considered pilot study sizes. The sample size re-estimation proce-
dures based on unbiased variance estimators all result in underpowered trials for small
pilot studies. The one-sample variance estimator results in a sample size re-estimation
which considerably overpowers the trials. The performance of the procedure with the
one-sample variance estimator improves as the placebo group mean µP decreases be-
cause a decreasing µP corresponds to a smaller between-group variability and, thus, to a
smaller bias of the variance estimator. For the same reason, the power of the procedure
8
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Figure 1: Power of different sample size re-estimation procedures depending on the pilot study size
n1. The desired power of 80% is marked as a dashed grey line.
based on the one-sample variance estimator is closer to the target power when the por-
tion of the sample size allocated to the placebo group decreases. Moreover, the power
of the re-estimation procedure with the Xing-Ganju estimator decreases as the sample
size allocation becomes unbalanced since this corresponds to an increase of the block
size from three to six resulting in an higher variability of the estimator. The sample size
re-estimation procedures based on the unbiased one-sample variance estimator and the
unblinded pooled variance estimator have a higher power than the re-estimation based
on the Xing-Ganju estimator, but also do not meet the target power for small internal
pilot studies. Additionally, among the sample size re-estimation procedures based on
unbiased variance estimators, the Xing-Ganju variance estimator has the slowest con-
vergence against the target power, especially for scenarios with an unbalanced sample
size allocation. However, as mentioned before, using the unbiased one-sample variance
estimator and the unblinded pooled variance estimator has the disadvantage of requir-
ing information on the parameters in the alternative and unblinding, respectively.
Next we compare the distribution of the final sample size for the sample size re-
estimation procedures with the one-sample variance estimator and the Xing-Ganju
variance estimator, that are the procedures with the largest and the smallest power,
respectively.
Figure 2 shows the variability of the final sample size for both procedures decreases as
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Figure 2: Median and interquartile range of the distribution of the final sample size depending on the
pilot study size n1. The dashed grey lines mark the sample size of the fixed design.
the internal pilot study sample size n1 increases. The variability of the final sample
size from the procedure based on the Xing-Ganju variance estimator is clearly larger
than the variably from the procedure based on the one-sample approach. These find-
ings are in alignment with what was observed in two-arm trials. For the re-estimation
procedure based on the one-sample variance estimator, the median of the final sample
size is larger then the sample size of a fixed design and constant in n1. In contrast, the
median of the final sample size of the re-estimation procedure based on the Xing-Ganju
variance estimator approaches the sample size of the fixed design from below as the
internal pilot study sample size n1 increases.
4.4. Type I error rate
The type I error rate in designs with a sample size adjustment must be assessed
for inflation since a general regulatory requirement for the conduct of adaptive clinical
trials is the control of the type I error rate. The sample size re-estimation is performed
for the test of the global hypotheses H0. However, when testing this hypothesis, the
intersection-union test principle is applied rejecting the global hypothesis at signifi-
cance level α only if all local hypotheses can be rejected at significance level α. As a
consequence, the actual type I error for the global hypothesis is in general not α but
smaller. Hence, if the sample size re-estimation procedure controls the local type I error
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rates, control of the global type I error rate is ensured. When studying the power, we
assumed that superiority of the experimental treatment and the reference over placebo
is tested with the margins δEP = δRP = 0. We study the type I error rate for the same
setting. However, with δER > 0, there is not combination of means (µE, µR, µP ) such
that the means are at the boundary of all three local hypotheses HER0 , H
EP
0 , and H
RP
0 .
Therefore, we study the type I error rate separately for the hypothesis HER0 and for
the hypotheses HEP0 , H
RP
0 . The parameters for the simulation study of the type I error
rate are listed in Table 5.
Table 5: Scenarios for the Monte Carlo simulation study of the type I error rate.
Parameter Values
One-sided significance level α 0.025
Target power 1− β 0.8
Superiority margins δEP , δRP δEP = δRP = 0
Non-inferiority margin δER δER = 0.2, 0.3, 0.4, 0.5
Means µE and µR in the alternative H1 µE = µR = 0
Mean µP µP = 0.6, 0.9
Standard deviation σ in the alternative H1 σ = 1
Sample size allocation nE : nR : nP 1:1:1, 3:2:1
Pilot study sample size n1 n1 = 30, 90, 150, . . . , 390
When simulating the type I error rate of the test for the null hypothesis HER0 , the ex-
perimental group mean and the reference group mean in the null hypothesis are defined
as µE,0 = δER and µR,0 = 0. In the case of simulating the type I error rate of the test
for the null hypotheses HEP0 and H
RP
0 , the means are chosen as µE,0 = µR,0 = µP . The
placebo group mean µP is in both cases defined as listed in Table 5. The simulated
type I error rates are based on 50 000 Monte Carlo replications which corresponds to a
Monte Carlo error of 0.0007 for a simulated type I error rate of 0.025. The simulated
type I error rates for the tests of the null hypotheses HER0 and H
EP
0 are summarized as
box plots in Figure 3 for the different sample size re-estimation procedures. The results
for the null hypothesis HRP0 are not shown here since they are identical to the results
for the null hypothesis HEP0 .
Figure 3 shows that all sample size re-estimation procedures on average slightly inflate
the type I error rate of the test for the non-inferiority hypothesis HER0 by about 0.0005.
The type I error rate of the test for the superiority hypothesis HEP0 is inflated when
the sample size re-estimation is conducted with the Xing-Ganju estimator or unblinded
with the pooled variance estimator. The magnitude of the inflation is the same as for
the test forHER0 . The sample size re-estimation procedure with the one-sample variance
estimator does not inflate the type I error rate of the test for the superiority hypothesis
HEP0 .
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Figure 3: Type I error rates for tests of the hypotheses HEP
0
and HER
0
. The dashed black line shows
the significance level α = 0.025 and the dashed grey lines mark the significance level plus/minus two
times the Monte Carlo error. Each box plot summarizes the results of 112 scenarios.
5. A sample size inflation factor for the Xing-Ganju procedure
None of the proposed sample size re-estimation procedures meets the desired power
for all pilot study sizes in the considered range. This motivates introducing a factor to
resize the re-estimated sample size such the desired power is met. Zucker et al. [43]
proposed a resizing coefficient for the re-estimated sample size in a two-arm trial setting.
For the sake of completeness, we present the general idea before applying it to three-arm
trials. Let B(n) be the power function of the testing problem for which the sample size
re-estimation is performed, n(σ2) the corresponding sample size as a function of the
nuisance parameter, and fσˆ2(·) the density of the nuisance parameter estimator. Then,
the power of the design with sample size adjustment can be approximated by
Power ≈
∫
∞
0
B (n˜ (x)) fσˆ2(x)dx
with n˜ (x) = max{n(x), n1}. This integral only approximates the power of the design
with sample size re-estimation because by considering the power function B(n) of the
fixed design we ignore that the distribution of the test statistic is not independent of the
nuisance parameter estimate from the pilot study. The resizing coefficient ζ ∈ (0,∞)
is the solution to the equation
∫
∞
0
B (n˜ζ (x)) fσˆ2(x)dx = 1− β. (4)
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The final sample size n˜ζ(·) is the maximum of the pilot study size and the resized
re-estimated sample size, that is
n˜ζ (x) = max{ζ · n(x), n1}.
In the ‘gold standard’ design, the power function B(n) is given by Equation (1) and
sample size formula n(σ2) by Equation (3). The densities fσˆ2(·) for the nuisance pa-
rameter estimators presented in Section 4.1 are calculated in Appendix Appendix A.
In this section, we focus on the Xing-Ganju variance estimator σˆ2XG. We refer to the
re-sizing factor as inflation factor since the final sample size from the re-estimation
must be inflated. As shown in Appendix Appendix A, the Xing-Ganju variance esti-
mator σˆ2XG follows a stretched chi-square distribution with (b − 1) degrees of freedom
with b the number of blocks in the randomization scheme. The stretching factor of the
stretched chi-square distribution depends on the standard deviation σ, the pilot study
sample size n1, and randomized block sizes. The pilot study size n1 and the randomized
block sizes are known before conducting the study. The standard deviation σ is un-
known which motivates the use of an internal pilot study in the first place. Therefore,
the questions remains whether the inflation factor ζ must be calculated based on the
re-estimate standard deviation or if it is constant in the standard deviation σ in which
case the inflation factor ζ could be calculate beforehand based on the pilot study size
and the block size. In the following, we study the effect of the standard deviation σ on
the re-sizing factor for the scenarios from Table 3. In Figure 4 the re-sizing factor ζ is
plotted against σ for various pilot study sizes n1. The size of the randomized blocks for
allocations 1:1:1 and 3:2:1 are three and six, respectively.
Figure 4 shows that the factor ζ is constant in the standard deviation σ for small pilot
study sizes (n1 = 30, 60). For larger pilot study sample sizes (n1 ≥ 90), the factor ζ
increases in σ first and becomes constant for larger standard deviations σ. For small
standard deviations σ, the factor ζ decreases as the standard deviation decreases since
the smaller the standard deviation the smaller is the difference between required sam-
ple size of the fixed design and the pilot study. For instance, for the scenario with
µP = 0.9, σ = 0.55, and allocation 3:2:1, the sample size of the fixed design is 134.
In this case, the factor ζ for an internal pilot study of size n1 = 120 would depend on
the assumed standard deviation. Moreover, for some pilot studies sizes, the re-sizing
factor cannot be calculated since the pilot study is already larger than the final sample
size of the fixed design. Concluding, the sample size inflation factor ζ is constant for
practical relevant scenarios in which the pilot study sample size is not almost as big
as the required sample size of the fixed design. Therefore, when we study the power
of the sample size re-estimation design with inflated sample size, we calculate the fac-
tor based on the pilot study size and the block size for a standard deviation σ in the
constant range of the inflation factor ζ . Next, we study the power of the sample size
re-estimation design when the re-estimated sample size is adjusted with the factor ζ .
We again consider the scenarios from Table 3. The results are based on 15 000 Monte
Carlo simulations. Figure 5 shows that applying the re-sizing factor to the re-estimated
sample size results in a re-estimation procedure which meets the target power for all
considered internal pilot study sizes. Moreover, the sample size re-estimation based
on the Xing-Ganju estimator and a re-sized sample size is the only one of the studied
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Figure 4: Sample size re-sizing factor ζ depending on the standard deviation σ. A reference line at
ζ = 1 is shown in black.
re-estimation procedures which meets the desired power for all considered pilot study
sample sizes. However, inflating the re-estimated sample size with a factor ζ also in-
creases the variability of the re-estimated sample size. As seen in Figure 4, the inflation
factor ζ increases when the internal pilot study decreases or the block size increases.
The simulation of the type I error rate of the sample size re-estimation procedure with
the Xing-Ganju estimator and sample size re-sizing factor is performed analogously to
the simulation study in Section 4.4. The type I error rate of the procedures with and
without re-sizing factor are similar and will not be shown here.
In theory, the presented approach for calculating a sample size re-sizing factor ζ by solv-
ing Equation (4) can be applied analogously to the other variance estimators. However,
in contrast to the Xing-Ganju estimator, the distribution of the one-sample variance
estimator does depend on the true means and the factor ζ depends on the unknown
standard deviation σ. Therefore, the factor ζ cannot be calculated prior to the start of
the pilot study without making assumptions on the standard deviation.
6. Discussion
In this manuscript, we studied blinded sample size re-estimation for three-arm non-
inferiority trials in the ‘gold standard’ design with non-inferiority defined by an absolute
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Figure 5: Power of designs with sample size adjustment with and without inflated sample size depending
on the internal pilot study sample size n1. The desired power of 80% is marked as a dashed grey line.
margin. The re-estimation procedures are based on an estimator of the nuisance param-
eter obtained from the results of an internal pilot study. Transferring ideas from sample
size re-estimation in two-arm trials, as blinded variance estimators we considered the
one-sample variance estimator, a bias adjusted version of the one-sample variance esti-
mator, and the Xing-Ganju estimator which is unbiased and based on randomized block
sums. The pooled variance estimator from the unblinded data was included for the sake
of comparison. A Monte Carlo simulation study showed that the blinded sample size
re-estimation procedure based on the one-sample variance estimator in general results
in overpowered trials, except when the between-group variability and the internal pilot
study sample size are small. The sample size re-estimation based on the other variance
estimators, which are all unbiased, underpower trials for small internal pilot study sam-
ple sizes. Moreover, we introduced an inflation factor for the sample size re-estimated
based on the Xing-Ganju estimator. The sample size inflation factor is calculated based
one the internal pilot study sample size and the block size for a specific alternative and
does not depend on the nuisance parameter σ. The resulting sample size re-estimation
procedure is the only procedure which meets the target power for all considered internal
pilot study sizes. The different sample size re-estimation procedures slightly inflate the
type I error rate. However, procedures for controlling the type I error rate in designs
with sample size re-estimation based on an internal pilot study have been suggested
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[46–48] and can be applied easily to the sample size re-estimation procedure proposed
in this article. Concluding, sample size re-estimation in three-arm non-inferiority tri-
als should be performed based on the Xing-Ganju estimator if the data is available in
randomized blocks and the re-estimated sample size should be inflated with the factor
ζ as presented in Section 5. Alternatively, if overpowering a trial is not an issue and,
in particular, if the between-group variability is small, the sample size re-estimation
should be conducted based on the one-sample variance estimator.
We studied sample size re-estimation for a non-inferiority hypothesis defined by an
absolute margin. Non-inferiority can also be defined based on the ratio of mean differ-
ence, that is (µE − µP )/(µR − µP ) [7]. The resulting hypothesis is in general referred
to as the retention-of-effect hypothesis. For the retention-of-effect hypothesis, the out-
come variance σ2 is still the nuisance parameter and the estimators presented in this
manuscript can be considered to estimate σ2 from results of the internal pilot study.
Therefore, a similar performance of the different sample size re-estimation approaches
can be expected in a design with non-inferiority defined by the retention-of-effect hy-
pothesis.
Adjusting a primary outcome for baseline covariates can help minimizing the bias
of a statistical analysis and additionally improve the analysis’ efficiency [49]. Future
research on sample size re-estimation in three-arm trials could focus on designs with
baseline covariates. For two-arm trials with covariate adjustment, Friede and Kieser
[47] studied sample size re-estimation based on a one-sample variance estimator and
Ganju and Xing [22] proposed a sample size re-estimation procedure based on random-
ized block sums. Friede and Kieser [23] studied sample size re-estimation in internal
pilot study designs with ANCOVA based on a one-sample variance estimator. These
approaches could be extended to three-arm trials in the ‘gold standard’ design.
Appendix A. Distributions of the blinded variance estimators
In this appendix we calculate the distribution of the blinded variance estimators.
Similar results for two-arm trials were obtained by Friede and Kieser (2013) [24]. In
this appendix we denote the blinded sample by Yn1 = (Y1, . . . , Yn1). For known group
sample sizes n1,k, k = E,R, P , the vector Yn1 is multivariate normally distributed
with mean vector µ and variance matrix σ2In1. The mean vector µ is an unknown
permutation of the vector with n1,k entries equal to µk for k = E,R, P . Furthermore,
we recall the following theorem which follows from [50, Theorem 7.3].
Theorem 1. Let Y ∼ Nn(µ,V) be multivariate normally distributed with µ ∈ Rn,
V ∈ Rn×n, |AV| 6= 0, A = A′ ∈ Rn×n, and k = rk(AV) = rk(A). Then, Y′AY ∼
χ2k(λ) with λ = µ
′Aµ if and only if AV is idempotent.
Appendix A.1. One-sample variance estimator
To determine the distribution of the one-sample variance estimator σˆ2OS, we define
the matrix A := 1
σ2
Pn with Pn the centralizing matrix of dimension n. We note the
relation
Y′AY =
n1 − 1
σ2
σˆ2OS.
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With Theorem 1 it follows that
Y′AY ∼ χ2n1−1(λ)
with
λ =
1
σ2
∑
k=E,R,P
nk(µk − µ¯)
2.
Therefore, the one-sample variance estimator follows a stretched noncentral chi-squared
distribution
σˆ2OS ∼
σ2
n1 − 1
χ2n1−1(λ).
The density function fσˆ2
OS
is given by
fσˆ2
OS
(x) = g
(
x
(n1 − 1)
σ2
)
(n1 − 1)
σ2
with g the density of a χ2n1−1(λ)-distributed random variable.
Appendix A.2. Xing-Ganju variance estimator
The variance estimator σˆ2XG is based on the block sums Tk with k = 1, . . . , b = n1/m.
We define the group sample sizes within a block as mk, k = E,R, P , with m the block
size. Then, the block sums are normally distributed,
Ti ∼ N
(
mEµE +mRµR +mPµP , mσ
2
)
.
Applying Theorem 1 gives the distribution of σˆ2XG, that is
σˆ2XG ∼
mσ2
n1 −m
χ2b−1.
The density function fσˆ2
XG
is given by
fσˆ2
XG
(x) = g
(
x
(n1 −m)
mσ2
)
(n1 −m)
mσ2
with g the density of a χ2b−1-distributed random variable.
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